Fexofenadine
Classification
Second-Generation H1 Antihistamine
Selective peripheral H1 receptor inverse agonist
Active metabolite of terfenadine
Parent class: Histamine & Antihistamines
Mechanism of Action
Fexofenadine selectively blocks peripheral H1 receptors.
Effects:
Key Feature:
Pharmacologic Background
Fexofenadine is the active metabolite of terfenadine.
Terfenadine was removed from the market due to QT prolongation and torsades risk (CYP3A4 inhibition interactions).
Fexofenadine:
Pharmacokinetics
Absorption reduced by:
Aluminum/magnesium antacids
Fruit juices (apple, orange, grapefruit)
Separate dosing from antacids by at least 2 hours.
Indications
Effective for:
Sneezing
Itching
Rhinorrhea
Less effective for:
Dosing (Adult)
60 mg PO twice daily
OR 180 mg PO once daily
Dose adjustment in renal impairment.
Adverse Effects
Generally very well tolerated.
Possible:
Headache
Mild nausea
Rare dizziness
Sedation:
Contraindications / Cautions
Drug Interactions
Aluminum/magnesium antacids ↓ absorption
Fruit juice ↓ bioavailability
Minimal CYP interaction
No meaningful QT risk at therapeutic doses
Clinical Pearls
Least sedating of the second-generation H1 blockers.
Preferred in patients requiring full daytime alertness.
Safe cardiovascular profile compared to its predecessor (terfenadine).
Does not significantly impair cognition or psychomotor function.
Not effective for nasal congestion as monotherapy.
Comparison Within Class
| Drug | Sedation Risk | Elimination | Unique Feature |
| Loratadine | Very low | Hepatic | Active metabolite = desloratadine |
| Cetirizine | Low | Renal | Slightly more sedating |
| Levocetirizine | Low | Renal | R-enantiomer refinement |
| Fexofenadine | Minimal | Renal/Fecal | Least sedating; safe QT profile |
Related Pages